- Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
On 6ix: 6ix.com/news/pharvaris-announces-positive-topline-data-rapide-3-pivotal-study-confirming-potential
Story so far
- Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
- Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
- Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Earlier from Pharvaris
- Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
- Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
- Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
- Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
- Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Later from Pharvaris
- Pharvaris Outlines 2026 Strategic Priorities
- Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
- Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
- Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
- Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Follow Pharvaris into a list and get an email when it puts out news.
Follow Pharvaris